CHEST Physician
-
Small trial shows lower ARDS rate, mortality with sivelestat following cardiopulmonary bypass
Nicholas Villalobos, MD, said that while sivelestat may not represent a single solution for ARDS, evidence that it can temper the inflammatory cascade is positive.
-
When less is more: Ultrasound’s role in deresuscitation
Certain bedside ultrasound techniques may help guide fluid deresuscitation in septic shock by identifying pulmonary and venous congestion in real time.
-
An unfortunate necessity: The DME moratorium and the future of out-of-hospital respiratory care
The DME moratorium from CMS is justified but fails to address inherent problems within the system itself.
-
LGBTQ+ health in focus: A Pride Month call to action
Let us recommit to a principle of care that surpasses clinical excellence; one that is inclusive, compassionate, and just.
-
Top reads from the CHEST journal portfolio – May 2026
Read new research from the journal portfolio on proximal hypoglossal nerve stimulation, shared decision-making in lung cancer screening, and lactate clearance in postoperative cardiac surgery care.
-
Advocating for change based on pulse oximetry research
Thomas Valley, MD, MS, shares how he advocates for systemwide change based on his research in pulse oximeter inaccuracies due to skin tone and encourages other clinicians to ask important questions that will improve patient care.
-
Advancing excellence: Why I pursued the CHEST CCAPP certification
The CCAPP certification demonstrates not only competence but also commitment to patients, teams, and the profession.
-
When oil infrastructure burns: What pulmonary clinicians should know
Recent conflict in the Middle East sheds light on oil fires as respiratory exposure events. Pulmonary clinicians need to be prepared to treat both acute and chronic symptoms from these exposures.
-
Navigating normotensive shock
Authors discuss the role normotensive shock plays in PE risk stratification according to new AHA guidelines on PE classification and management.
-
Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD
Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.
